Related Experiment Video
Updated: Mar 19, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
Paraneoplastic syndrome mimicking progressive supranuclear palsy
Deepa Dash1, Rima Choudhary1, Bhargavi Ramanujam1
1Department of Neurology, All India Institute of medical sciences, Ansari Nagar East, New Delhi, Delhi 110029, India.
A rare paraneoplastic syndrome mimicking progressive supranuclear palsy (PSP) was identified in a patient with small cell lung cancer. Treatment combining immunomodulation and chemotherapy led to symptom improvement, highlighting a treatable neurological complication of cancer.
Area of Science:
- Neurology
- Oncology
- Immunology
Background:
- Paraneoplastic syndromes are rare complications of cancer, often presenting with neurological symptoms.
- Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder characterized by parkinsonism and other neurological deficits.
- The co-occurrence of PSP phenotype with malignancy is exceptionally uncommon.
Observation:
- A patient presented with rapidly progressive parkinsonism, clinically resembling PSP.
- Diagnostic workup revealed small cell carcinoma of the lung.
- The patient was seropositive for onconeural antibodies, suggesting an autoimmune response targeting neural tissue.
Findings:
- The patient's presentation was consistent with a paraneoplastic neurological disorder.
- Treatment involved a combination of immunomodulatory therapy and chemotherapy for the lung cancer.
- A significant improvement in the patient's neurological symptoms was observed post-treatment.
Implications:
- This case underscores the importance of considering paraneoplastic syndromes in patients with atypical parkinsonism.
- Early diagnosis and combined oncological and immunological treatment can lead to favorable outcomes.
- Further research into onconeural antigens and their role in paraneoplastic PSP-like syndromes is warranted.
Related Concept Videos
Parkinson's Disease: Overview
Neural Regulation
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Postsynaptic Potential (PSP)
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

